Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Voice Acoustics in Healthy Adults (taVNS-VOICE)
Acute Effects of Unilateral and Bilateral Transcutaneous Auricular Vagus Nerve Stimulation on Acoustic Voice Parameters and Autonomic Function in Healthy Adults: A Randomized, Sham-Controlled, Three-Period Crossover Trial
This study aims to investigate the immediate effects of transcutaneous auricular vagus nerve stimulation (taVNS) on voice characteristics and autonomic function in healthy adults.
A total of 36 healthy adults aged 18-30 years will participate in this randomized, sham-controlled, three-period crossover trial. Each participant will receive three interventions in a randomized order: unilateral active taVNS, bilateral active taVNS, and sham stimulation. Each intervention will last 20 minutes, with at least seven days between visits.
Voice characteristics will be evaluated before and after each intervention using acoustic analysis. The primary outcome will be shimmer, a measure of variation in voice amplitude. Secondary outcomes will include jitter, harmonics-to-noise ratio, and fundamental frequency. Perceived vocal effort, heart rate, and pulse rate variability will also be assessed.
The study will compare the immediate effects of unilateral, bilateral, and sham stimulation on voice stability and explore possible relationships between voice changes and autonomic responses.
Studieoversikt
Status
Status
Forhold
Forhold
Intervensjon / Behandling
Intervensjon / Behandling
Detaljert beskrivelse
This prospective, randomized, sham-controlled, three-period crossover trial will investigate the acute effects of unilateral and bilateral transcutaneous auricular vagus nerve stimulation (taVNS) on acoustic voice parameters and autonomic function in healthy adults.
Thirty-six participants aged 18-30 years will be allocated to one of six intervention sequences (ABC, ACB, BAC, BCA, CAB, or CBA). Each participant will complete three intervention visits separated by a washout period of at least seven days.
The intervention conditions will include: (A) unilateral active stimulation of the left cymba conchae, (B) bilateral active stimulation of the cymba conchae, and (C) bilateral sham stimulation applied to the earlobes with an initial brief sensory stimulation followed by gradual reduction of current to zero. Stimulation will be delivered using Nurosym devices at 20 Hz and 200 μs for 20 minutes. Active stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level.
Acoustic voice assessment will involve three recordings of sustained /a/ phonation before and after each intervention. Recordings will be analyzed using Praat software. Shimmer (%) will be the primary outcome, while jitter (%), harmonics-to-noise ratio (dB), and fundamental frequency (Hz) will be secondary outcomes.
Perceived vocal effort will be assessed using a 100-mm visual analogue scale. Autonomic responses will be evaluated using pulse rate variability measurements obtained with the Polar Verity Sense device, including RMSSD, SDNN, and mean heart rate.
Primary analyses will use linear mixed-effects models to compare changes across intervention conditions while accounting for repeated measurements and study periods. Adverse events and stimulation tolerability will be monitored throughout the study.
Studietype
Studietype
Registrering (Antatt)
Registrering
Fase
Fase
- Ikke aktuelt
Kontakter og plasseringer
Studiekontakt
Studiekontakt
- Navn: Sefa Haktan Hatık Principal Investigator, PhD, MSc, Physiotherapist
- Telefonnummer: +90 505 876 1553
- E-post: haktanhtk@gmail.com
Deltakelseskriterier
Kvalifikasjonskriterier
Kvalifikasjonskriterier
Alder som er kvalifisert for studier
Tar imot friske frivillige
Kjønn som er kvalifisert for studier
Beskrivelse
Inclusion Criteria:
- Adults aged 18-30 years.
- Self-reported good general health without known systemic diseases preventing safe participation.
- Native Turkish speakers.
- No current hoarseness, vocal strain, or known laryngeal/voice disorders.
- No current use of cigarettes, electronic cigarettes, heated tobacco, or other nicotine products.
- Ability and willingness to attend three intervention visits separated by at least 7 days.
- Ability to understand and follow study procedures.
- Provision of written informed consent.
Exclusion Criteria:
- Known cardiovascular disease, clinically significant arrhythmia, uncontrolled hypertension or hypotension, or unexplained syncope.
- History of epilepsy, seizures, or serious neurological disorders.
- Known vocal fold or laryngeal pathology, chronic voice disorders, previous laryngeal surgery, or significant hoarseness.
- Active respiratory infection, laryngitis, sore throat, or febrile illness.
- Ear infections, wounds, dermatological lesions, hypersensitivity, or piercings interfering with electrode placement.
- Pacemakers, implantable cardioverter-defibrillators, or other active electronic implants.
- Pregnancy or suspected pregnancy.
- Current tobacco or nicotine use.
- Regular use of medications significantly affecting autonomic function or voice, including beta-blockers, antiarrhythmics, anticholinergics, sedatives, or psychoactive medications.
- Failure to comply with pre-assessment restrictions concerning caffeine, alcohol, vigorous exercise, or vocal loading; visits may be rescheduled when possible.
- Clinically significant intolerance or adverse reactions to stimulation requiring discontinuation.
Studieplan
Hvordan er studiet utformet?
Designdetaljer
- Primært formål: Grunnvitenskap
- Tildeling: Randomisert
- Intervensjonsmodell: Crossover-oppdrag
- Masking: Enkelt
Antall våpen
Våpen og intervensjoner
Deltakergruppe / ArmDeltakergruppe / Arm |
Intervensjon / BehandlingIntervensjon / Behandling |
|---|---|
|
Eksperimentell: Sequence ABC
Unilateral active taVNS, followed by bilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
|
Eksperimentell: Sequence ACB
Unilateral active taVNS, followed by bilateral sham stimulation, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
|
Eksperimentell: Sequence BAC
Bilateral active taVNS, followed by unilateral active taVNS, then bilateral sham stimulation. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
|
Eksperimentell: Sequence BCA
Bilateral active taVNS, followed by bilateral sham stimulation, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
|
Eksperimentell: Sequence CAB
Bilateral sham stimulation, followed by unilateral active taVNS, then bilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
|
Eksperimentell: Sequence CBA
Bilateral sham stimulation, followed by bilateral active taVNS, then unilateral active taVNS. Each intervention lasts 20 minutes, with a washout period of at least 7 days between visits. |
Active transcutaneous auricular vagus nerve stimulation using the Nurosym device, applied to the left cymba conchae at 20 Hz and 200 μs for 20 minutes. Stimulation intensity will be individually adjusted to a comfortable, non-painful sensory level. Bilateral sham stimulation with electrodes placed on both earlobes. Brief initial sensory stimulation will be followed by gradual reduction of current to zero (fade-out sham). The total procedure duration will be 20 minutes. |
Hva måler studien?
Primære resultatmål
Primære resultatmål
Resultatmål |
Tiltaksbeskrivelse |
Tidsramme |
|---|---|---|
|
Change in Shimmer (%)
Tidsramme: At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.
|
Shimmer (%) will be measured using Praat software from three sustained /a/ phonations. The stable middle 3-second segment of each recording will be analyzed, and the mean of three measurements will be used. Change will be calculated as post-intervention minus baseline shimmer. |
At each of three visits: before intervention and after the 20-minute intervention and 5-minute PRV recording; visits separated by at least 7 days.
|
|
Change in Jitter (%)
Tidsramme: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
Change in cycle-to-cycle fundamental frequency variation, measured using Praat software from three sustained /a/ phonations. |
At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
|
Change in Harmonics-to-Noise Ratio (dB)
Tidsramme: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
Change in voice harmonic-to-noise ratio, measured using Praat software from three sustained /a/ phonations. |
At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
|
Change in Fundamental Frequency (Hz)
Tidsramme: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
Change in mean fundamental frequency (F0), measured using Praat software from three sustained /a/ phonations. |
At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
|
Change in Perceived Vocal Effort (mm)
Tidsramme: At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
Change in perceived vocal effort assessed using a 100-mm visual analogue scale (VAS), where higher scores indicate greater perceived vocal effort. |
At each of three visits: baseline and after the 20-minute intervention and subsequent 5-minute PRV recording; visits separated by at least 7 days.
|
|
Change in RMSSD (ms)
Tidsramme: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
Change in the root mean square of successive differences (RMSSD), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense. |
At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
|
Change in SDNN (ms)
Tidsramme: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
Change in the standard deviation of normal-to-normal pulse intervals (SDNN), calculated from 5-minute pulse rate variability recordings using Polar Verity Sense. |
At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
|
hange in Mean Heart Rate (bpm)
Tidsramme: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
Change in mean heart rate measured using Polar Verity Sense during 5-minute recordings. |
At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
|
Change in LF/HF Ratio
Tidsramme: At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
Exploratory analysis of the low-frequency to high-frequency power ratio derived from pulse rate variability recordings. |
At each of three visits: 5-minute baseline recording and 5-minute recording immediately following the 20-minute intervention; visits separated by at least 7 days.
|
Samarbeidspartnere og etterforskere
Sponsor
Sponsor
Publikasjoner og nyttige lenker
Generelle publikasjoner
- Faul F, Erdfelder E, Buchner A, Lang AG. Statistical power analyses using G*Power 3.1: tests for correlation and regression analyses. Behav Res Methods. 2009 Nov;41(4):1149-60. doi: 10.3758/BRM.41.4.1149.
- Choi SH, Choi WS, Han GY. Acoustic voice changes induced by transcutaneous auricular vagus nerve stimulation. Clinical Archives of Communication Disorders. 2025;10(3):143-153. doi:10.21849/cacd.2025.10.3.3.
- Yoshida Y, Okayama S, Fujihara D, Taniyama M, Yamada A, Fukui M, Doi N, Takahashi R, Tanabe A, Ogaki S, Hattori S, Iwai A, Nakamura M, Doi N, Saito Y. Effects of Transcutaneous Auricular Vagus Nerve Stimulation on Hemodynamics and Autonomic Function During Exercise Stress Tests in Healthy Volunteers. Circ Rep. 2025 Apr 11;7(5):315-322. doi: 10.1253/circrep.CR-24-0136. eCollection 2025 May 9.
Studierekorddatoer
Studer hoveddatoer
Studiestart (Antatt)
Studiestart
Primær fullføring (Antatt)
Primær fullføring
Studiet fullført (Antatt)
Studiet fullført
Datoer for studieregistrering
Først innsendt
Først innsendt
Først innsendt som oppfylte QC-kriteriene
Først innsendt som oppfylte QC-kriteriene
Først lagt ut (Faktiske)
Først lagt ut
Oppdateringer av studieposter
Sist oppdatering lagt ut (Faktiske)
Sist oppdatering lagt ut
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Siste oppdatering sendt inn som oppfylte QC-kriteriene
Sist bekreftet
Sist bekreftet
Mer informasjon
Begreper knyttet til denne studien
Nøkkelord
Andre studie-ID-numre
Andre studie-ID-numre
- TAVNS-VOICE-CO-2026-01
Plan for individuelle deltakerdata (IPD)
Planlegger du å dele individuelle deltakerdata (IPD)?
IPD-planbeskrivelse
Individual participant data will not be shared with external researchers to protect participant confidentiality and privacy. Study findings will be reported in aggregate form in scientific publications.
Legemiddel- og utstyrsinformasjon, studiedokumenter
Studerer et amerikansk FDA-regulert medikamentprodukt
Studerer et amerikansk FDA-regulert enhetsprodukt
Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .